The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a phase three clinical trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
HoFH is a genetic condition that causes dangerously high levels of LDL cholesterol that are difficult to control with existing medications. Patients with HoFH have two copies of the faulty gene that causes familial hypercholesterolemia (FH) and often respond poorly to conventional treatment. Uncontrolled LDL cholesterol leads to plaque building up in the arteries and FH patients face a high risk of coronary artery disease beginning as early as childhood.
Alirocumab is a monoclonal antibody approved by the U.S. Food and Drug Administration for treating high LDL cholesterol levels in adults alone or in combination with other lipid-lowering therapies. It boosts the body's ability to remove LDL cholesterol from circulation by blocking PCSK9, a protein that keeps LDL cholesterol circulating in the body. Alirocumab has been tested for use in a wide range of patients with high cholesterol, but the new placebo-controlled trial is the first to assess the efficacy and safety of the drug for patients with HoFH.
This trial is the largest randomized controlled interventional trial in adults with HoFH to date and offers important insights into the disease. Alirocumab is a potential new therapy that should be considered in appropriate patients with HoFH."
Dirk Blom, MD, PhD, head of the Division of Lipidology in the Department of Medicine at the University of Cape Town in Cape Town, South Africa and the study's lead author
The trial enrolled 69 patients with HoFH. Forty-five patients were randomly assigned to receive alirocumab via subcutaneous injection every two weeks for 12 weeks. The rest received placebo injections. All patients maintained their regular cholesterol medications and treatments, such as statins, ezetimibe, lomitapide and apheresis, but did not take any other PCSK9 inhibitors.
At 12 weeks, average LDL cholesterol levels among those receiving alirocumab were 26.9% lower than at the trial's start while LDL cholesterol levels among those receiving placebo rose by 8.6%, resulting in an average relative reduction of 35.6% among those receiving alirocumab, meeting the trial's primary endpoint. The average absolute reduction in LDL cholesterol in the patients receiving alirocumab was 62.8 mg/dL.
Alirocumab also substantially reduced other harmful lipids that are typically elevated in people with FH. On average, apolipoprotein B dropped by 29.8%, lipoprotein(a) dropped by 28.4%, non-high-density cholesterol dropped by 32.9% and total cholesterol dropped by 26.5% among those taking alirocumab compared to placebo.
The trial found alirocumab to be well-tolerated and no treatment-related serious adverse events occurred.
"This is a worthwhile potential treatment that helps to lower the LDL cholesterol, though a lot of patients still require additional therapy because the LDL cholesterol is so high at baseline. Unfortunately, there are also a small number of patients with specific mutations who do not respond, or only respond very poorly, to alirocumab," Blom said.
In the U.S., it is estimated that 1 in 250 adults have heterozygous FH and approximately 1 in 300,000 may have HoFH.
This study was funded by Regeneron Pharmaceuticals, makers of alirocumab.
Early cholesterol spikes fuel atherosclerosis by altering macrophages